| Japanese |
|---|
| Title | 副腎スキャン剤6β-Iodomethyl-19-Nor-Cholest-5(10)-en-3β-ol-131I (NCL-6-131I) と131I-19-Cholesterol (CL-19-131I) の比較研究 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 福地総逸*, 中嶋凱夫*, 三浦正*, 春山和見*, 木田利之**, 斎藤勝***, 中村護**** |
|---|
| Authors(kana) | |
|---|
| Organization | *福島県立医大第三内科, **福島県立医大放射線科, ***福島県立医大RI研究室, ****東北大学医学部放射線科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 13 |
|---|
| Number | 6 |
|---|
| Page | 775-779 |
|---|
| Year/Month | 1976/12 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 1970年Blairらは副腎に特異的に集積する放射性化合物131I-19-コレステロール(CL-19-131I)を合成し, 本剤が副腎疾患の診断, 特に副腎腫瘍の診断に有用であることを明らかにした. CL-19-131Iは, 1回静注してのち6〜8日目に副腎部をスキャンするだけなので患者に対する侵襲が少いという点ですぐれた薬剤であるが, 1mCiという多量の放射活性を有するスキャン剤を投与する必要があるので, 被曝量も多く, 繰返し検査を行えないという欠点があった. これに対し, 最近第一ラジオアイソトープ研究所(DRL)の合成した新副腎スキャン剤6β-iodomethyl-19-nor-cholest-5(10)-en-3β-ol-131I(NCL-6-131I)は, ラットで検討した所, CL-19-131Iの10倍の放射活性が副腎に集積するという. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | |
|---|
| English |
|---|
| Title | Comparative Study of Adrenal Scanning Agents, 6β-Iodomethyl-19-Nor-Cholest-5(10)-en-3β-ol-131I (NCL-6-131I) and 131I-19-Cholesterol (CL-19-131I) |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Soitsu FUKUCHI, Katsuo NAKAJIMA, Tadashi MIURA, Kazumi HARUYAMA, Toshiyuki KIDA, Masaru SAITO, Mamoru NAKAMURA |
|---|
| Authors(kana) | |
|---|
| Organization | Department of Internal Medicine, Department of Radiology and Radioisotope Laboratory, Fukushima Medical College, and Department of Radiology, Tohoku University School of Medicine |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 13 |
|---|
| Number | 6 |
|---|
| Page | 775-779 |
|---|
| Year/Month | 1976/12 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] In this paper, fundamental studies of 6β-iodomethyl-19-nor-cholest-en-3β-ol-131I (NCL-6-131I) for adrenal scanning agent were done in comparison with 131I-19-cholesterol (CL-19-131I). Urinary excretion of radioactivity after NCL-16-131I and CL-19-131I was estimated in 5 patients (3 primary aldosteronism, 1 idiopathic aldosteronism and 1 essential hypertension). Also radioactivities in plasma, adrenal adenoma and remaining adrenal gland obtained by surgery, 8 days after the intravenous administration of the adrenal scanning agents, were measured in 3 patients with primary aldosteronism. Urinary excretion of radioactivity was rapidly decreased to a half of that of the first day in the 4th day after the administration of NCL-6-131I. Radioactive concentrations were twice higher in adrenal adenoma and 3.4-9.4 times higher in the remaining adrenal gland of primary aldosteronism after NCL-6-131I than after CL-19-131I. Plasma contained similar amount of radioactivity after NCL-6-131I as after CL-19-131I. Therefore, ratio of radioactivity in adrenal adenoma to plasma was 115 after CL-19-131I, and 180-264 after NCL-6-131I. Radioactive ratio in adrenal gland to plasma was 18.7 after CL-19-131I and 56-198 after NCL-6-131I. No side effect was observed in these patients. From these results, it is concluded that smaller amount of NCL-6-131I (2μCi/kg, one tenth of CL-19-131I) is sufficient for visualization of adrenal tumor in patient with primary aldosteronism. Also fifty per cent of the radioiodocholesterol is suspected to be excreted between three and four days after administration of the dose. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | |
|---|